Key findings at the highest dose (12mg weekly): Up to 24% mean body weight reduction over 48 weeks Significant reductions in fasting glucose and insulin resistance markers Meaningful reductions in liver fat content, relevant for participants with metabolic-associated fatty liver disease Once-weekly subcutaneous dosing was generally well-tolerated For context, semaglutide at its approved dose achieves approximately 1517% body weight reduction over 68 weeks
For this drug, the ongoing SOUL trial has shown promising preliminary results, indicating a 14% reduction in the risk of MACE (84)
As insulin resistance worsens, the pancreas works increasingly hard to maintain glucose control
Clinical Trials and Results The TRIUMPH-1 Phase 3 clinical trial results are pivotal in assessing Retatrutide's potential
Furthermore, GLP-1 RAs have beneficial effects for reducing the risk of MI or endpoints composed of coronary events (e.g., MACE, cardiovascular mortality), while solid evidence on CCS, vasospastic angina, and MVA is lacking
Some practitioners adjust doses for individuals at extreme ends of the weight spectrum (under 120 lbs or over 300 lbs), but standard protocols use fixed dosing
